Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Front Microbiol ; 9: 832, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29780367

RESUMEN

Human T-lymphotropic virus 1 (HTLV-1) immortalizes T-cells and is the causative agent of adult T-cell leukemia/lymphoma (ATLL). HTLV-1 replication and transformation are governed by multiple interactions between viral regulatory proteins and host cell factors that remain to be fully elucidated. The present study investigated the impact of HTLV-1 infection on the expression of miR-34a, a microRNA whose expression is downregulated in many types of cancer. Results of RT-PCR assays showed that five out of six HTLV-1-positive cell lines expressed higher levels of miR-34a compared to normal PBMC or purified CD4+ T-cells. ATLL cell line ED, which did not express miR-34a, showed methylation of the miR-34a promoter. Newly infected PBMC and samples from 10 ATLL patients also showed a prominent increase in miR-34a expression compared to PBMC controls. The primary miR-34a transcript expressed in infected cell line C91PL contained binding motifs for NF-κB and p53. Pharmacological inhibition of NF-κB with Bay 11-7082 indicated that this pathway contributes to sustain miR-34a levels in infected cells. Treatment of infected cell lines with the p53 activator nutlin-3a resulted in a further increase in miR-34a levels, thus confirming it as a transcriptional target of p53. Nutlin-3a-treated cells showed downregulation of known miR-34a targets including the deacetylase SIRT1, which was accompanied by increased acetylation of p53, a substrate of SIRT1. Transfection of C91PL cells with a miR-34a mimic also led to downregulation of mRNA targets including SIRT1 as well as the pro-apoptotic factor BAX. Unlike nutlin-3a, the miR-34a mimic did not cause cell cycle arrest or reduce cell viability. On the other hand, sequestration of miR-34a with a sponge construct resulted in an increase in death of C91PL cells. These findings provide evidence for a functional role for miR-34a in fine-tuning the expression of target genes that influence the turnover of HTLV-1-infected cells.

2.
J Neuroinflammation ; 14(1): 58, 2017 03 20.
Artículo en Inglés | MEDLINE | ID: mdl-28320438

RESUMEN

BACKGROUND: Intravenous immunoglobulin (IVIG) is a polyspecific pooled immunoglobulin G preparation and one of the commonly used therapeutics for autoimmune diseases including those of neurological origin. A recent report in murine model proposed that IVIG expands regulatory T (Treg) cells via induction of interleukin 33 (IL-33). However, translational insight on these observations is lacking. METHODS: Ten newly diagnosed Guillain-Barré syndrome (GBS) patients were treated with IVIG at the rate of 0.4 g/kg for three to five consecutive days. Clinical evaluation for muscular weakness was performed by Medical Research Council (MRC) and modified Rankin scoring (MRS) system. Heparinized blood samples were collected before and 1, 2, and 4-5 weeks post-IVIG therapy. Peripheral blood mononuclear cells were stained for surface CD4 and intracellular Foxp3, IFN-γ, and tumor necrosis factor alpha (TNF-α) and were analyzed by flow cytometry. IL-33 and prostaglandin E2 in the plasma were measured by ELISA. RESULTS: The fold changes in plasma IL-33 at week 1 showed no correlation with the MRC and MRS scores at weeks 1, 2, and ≥4 post-IVIG therapy. Clinical recovery following IVIG therapy appears to be associated with Treg cell response. Contrary to murine study, there was no association between the fold changes in IL-33 at week 1 and Treg cell frequency at weeks 1, 2, and ≥4 post-IVIG therapy. Treg cell-mediated clinical response to IVIG therapy in GBS patients was associated with reciprocal regulation of effector T cells-expressing TNF-α. CONCLUSION: Treg cell expansion by IVIG in patients with autoimmune diseases lack correlation with IL-33. Treg cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to IVIG therapy.


Asunto(s)
Síndrome de Guillain-Barré , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Interleucina-33/sangre , Linfocitos T Reguladores/patología , Anciano , Anciano de 80 o más Años , Dinoprostona/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Estudios de Seguimiento , Síndrome de Guillain-Barré/sangre , Síndrome de Guillain-Barré/tratamiento farmacológico , Síndrome de Guillain-Barré/patología , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Valor Predictivo de las Pruebas , Índice de Severidad de la Enfermedad , Estadísticas no Paramétricas
3.
Indian Pediatr ; 54(12): 1052-1053, 2017 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-29317564

RESUMEN

BACKGROUND: Neonatal diabetes mellitus is a rare condition. CASE CHARACTERISTICS: A small for gestational age male, presented with neonatal onset diabetes mellitus, duodenal atresia, annular pancreas and gall bladder hypoplasia. OBSERVATION: Observation: A novel homozygous mutation p.K163R (c.488A>G) in the PDX1 gene was found. Parents were heterozygous for the same. MESSAGE: This case highlights the importance of establishing the genetic diagnosis in all cases of neonatal diabetes mellitus.


Asunto(s)
Diabetes Mellitus/genética , Obstrucción Duodenal/genética , Proteínas de Homeodominio/genética , Mutación/genética , Páncreas/anomalías , Enfermedades Pancreáticas/genética , Transactivadores/genética , Insuficiencia Pancreática Exocrina/genética , Vesícula Biliar/anomalías , Humanos , Recién Nacido , Atresia Intestinal , Masculino
4.
Indian Pediatr ; 53(9): 833-834, 2016 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-27771654

RESUMEN

BACKGROUND: Hepatocellular carcinoma is an uncommon complication described in patients with Budd-Chiari syndrome. CASE CHARACTERISTICS: A 12-year-old boy with Budd-Chiari syndrome, who was earlier treated with Transjugular intrahepatic porto-systemic shunt (TIPS), presented with acute onset hemoperitoneum and hypotension. OUTCOME: It was diagnosed to be a case of ruptured hepatocellular carcinoma. MESSAGE: Successful TIPS may not prevent the development of hepatocellular carcinoma, and children with Budd Chiari syndrome should be monitored for the same.


Asunto(s)
Síndrome de Budd-Chiari/complicaciones , Carcinoma Hepatocelular , Neoplasias Hepáticas , Carcinoma Hepatocelular/complicaciones , Carcinoma Hepatocelular/diagnóstico , Niño , Humanos , Neoplasias Hepáticas/complicaciones , Neoplasias Hepáticas/diagnóstico , Masculino , Derivación Portosistémica Intrahepática Transyugular
5.
Eur J Gastroenterol Hepatol ; 28(5): 567-75, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26904975

RESUMEN

OBJECTIVES: Budd-Chiari syndrome (BCS) is an uncommon cause of chronic liver disease in children. The literature on the management of pediatric BCS is scarce. Our aim was to determine the long-term outcome of patients undergoing a radiological intervention for the treatment of BCS. METHODS: Thirty-two children diagnosed with BCS between 2004 and 2014 were included. Data on the course of disease, medical management, response, and complications related to radiological interventions and outcome were collected. MAIN RESULTS: Twenty-five patients who were on regular follow-up were analyzed. The median age of the patients at presentation was 9 months (4.5-214). Sixteen patients initially received anticoagulation alone. This was associated with a high failure rate of 66%. Twenty patients underwent a radiological intervention in the form of angioplasty (n=7), hepatic vein stenting (n=3) or transjugular intrahepatic portosystemic shunt (TIPS) (n=14). Success with angioplasty was achieved in 43% of cases. Hepatic vein stenting was successful in 66%, whereas TIPS was successful in 72% of cases. TIPS was feasible in all patients. The median follow-up duration was 44 months (5-132). Four patients developed hepatopulmonary syndrome after a median period of 3 years (1.5-5.25) and one patient developed hepatocellular carcinoma. CONCLUSION: BCS commonly presents during infancy. Anticoagulation alone and angioplasty of the hepatic veins are associated with a high failure rate. Hepatic vein stenting or TIPS is feasible and efficacious in improving liver function, portal hypertension, and growth. It is associated with good long-term outcome and delays the need for liver transplantation, but may not prevent complications such as hepatopulmonary syndrome and hepatocellular carcinoma.


Asunto(s)
Angioplastia , Síndrome de Budd-Chiari/terapia , Venas Hepáticas , Derivación Portosistémica Intrahepática Transyugular , Radiografía Intervencional , Adolescente , Factores de Edad , Angioplastia/efectos adversos , Angioplastia/instrumentación , Anticoagulantes/uso terapéutico , Síndrome de Budd-Chiari/diagnóstico por imagen , Síndrome de Budd-Chiari/fisiopatología , Niño , Preescolar , Femenino , Venas Hepáticas/diagnóstico por imagen , Venas Hepáticas/fisiopatología , Humanos , Lactante , Masculino , Presión Portal , Derivación Portosistémica Intrahepática Transyugular/efectos adversos , Radiografía Intervencional/efectos adversos , Estudios Retrospectivos , Stents , Factores de Tiempo , Resultado del Tratamiento
6.
Sci Rep ; 6: 19592, 2016 Jan 22.
Artículo en Inglés | MEDLINE | ID: mdl-26796539

RESUMEN

Intravenous immunoglobulin G (IVIG) is used in the therapy of various autoimmune and inflammatory conditions. The mechanisms by which IVIG exerts anti-inflammatory effects are not completely understood. IVIG interacts with numerous components of the immune system including dendritic cells, macrophages, T and B cells and modulate their functions. Recent studies have reported that heme oxygenase-1 (HO-1) pathway plays an important role in the regulation of inflammatory response in several pathologies. Several therapeutic agents exert anti-inflammatory effects via induction of HO-1. Therefore, we aimed at exploring if anti-inflammatory effects of IVIG are mediated via HO-1 pathway. Confirming the previous reports, we report that IVIG exerts anti-inflammatory effects on innate cells as shown by the inhibitory effects on IL-6 and nitric oxide production and confers protection in experimental autoimmune encephalomyelitis (EAE) model. However, these effects were not associated with an induction of HO-1 either in innate cells such as monocytes, dendritic cells and macrophages or in the kidneys and liver of IVIG-treated EAE mice. Also, inhibition of endogenous HO-1 did not modify anti-inflammatory effects of IVIG. These results thus indicate that IVIG exerts anti-inflammatory effects independent of HO-1 pathway.


Asunto(s)
Antiinflamatorios/uso terapéutico , Hemo-Oxigenasa 1/metabolismo , Inmunoglobulinas Intravenosas/uso terapéutico , Animales , Antiinflamatorios/farmacología , Citoprotección/efectos de los fármacos , Células Dendríticas/efectos de los fármacos , Células Dendríticas/metabolismo , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Inducción Enzimática/efectos de los fármacos , Hemo-Oxigenasa 1/biosíntesis , Humanos , Inmunoglobulinas Intravenosas/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , Ratones Endogámicos C57BL , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Sustancias Protectoras/farmacología , Células RAW 264.7
8.
J Clin Immunol ; 35(5): 459-62, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26054576

RESUMEN

Mendelian susceptibility to mycobacterial disease (MSMD) is a rare condition characterized by clinical disease caused by weakly virulent mycobacteria. All genes mutated in MSMD patients are involved in IFN-γ immunity. Autosomal partial dominant (PD) interferon-γ receptor 1 (IFN-γR1) deficiency is the most frequent abnormality affecting the group of MSMD patients leading to impaired response of IFN-γ. We describe here a patient from India with disseminated infection due to Mycobacterium avium intracellulare (MAC) including multifocal osteomyelitis and BCG disease. A heterozygous mutation in exon 6 of IFNGR1 gene was identified, conferring an autosomal PD IFN-γR1 deficiency. Patient had recurrence of mycobacterial disease during antibiotic therapy for which subcutaneous IFN-γ was added as a modality of treatment for resistant MAC infection.


Asunto(s)
Complejo Mycobacterium avium/inmunología , Infección por Mycobacterium avium-intracellulare/diagnóstico , Osteomielitis/inmunología , Receptores de Interferón/genética , Antibacterianos/uso terapéutico , Niño , Quimioterapia Combinada , Genes Dominantes/genética , Humanos , India , Interferón gamma/uso terapéutico , Masculino , Mutación/genética , Infección por Mycobacterium avium-intracellulare/genética , Infección por Mycobacterium avium-intracellulare/terapia , Osteomielitis/genética , Osteomielitis/terapia , Receptor de Interferón gamma
9.
J Nucleic Acids ; 20102010.
Artículo en Inglés | MEDLINE | ID: mdl-20700417

RESUMEN

C-myc and Bcl2 are well characterized oncogenes that are capable of forming G-quadruplex structures. Promoter regions of C-myc and Bcl2 forming G-quadruplex structures are chemically synthesized and G-quadruplex structure is formed in presence of 100 mM potassium ion. Three different porphyrin drugs, namely TMPyP2, TMPyP3, and TMPyP4 are allowed to interact with quadruplex DNA complex and the site and nature of interaction are studied. Drug interactions with quadruplex DNA were carried out in different potassium ionic strengths using fluorescence spectroscopy. It is found that fluorescence hypochromicity decreases with an increase in ionic strength in the case of TMPyP4, TMPyP3, and TMPyP2. Fluorescence titration studies and Job plots indicate that four molecules of TMPyP4, two molecules of TMPyP3 and TMPyP2 are interacting with one molecule of quadruplex DNA.

10.
Inflammopharmacology ; 18(2): 59-64, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20143166

RESUMEN

Persistent infection with Helicobacter pylori confers an increased risk of peptic ulceration and gastric adenocarcinoma. Reactive oxygen and nitrogen species play a crucial role in the progression from normal gastric mucosa to cancer. The aim of the present study was to investigate the plasma malondialdehyde and nitric oxide levels in H. pylori related gastroduodenal diseases and associate their levels with gastric pathology and genotypes of H. pylori. Malondialdehyde and nitric oxide levels in plasma samples of 250 subjects were spectrophotometrically determined. Subsequently, genotypic and histopathological assessment was performed in gastric biopsies obtained during endoscopy. The levels of MDA and NO exceeded in subjects infected with genotype-1 of Hp than those with other genotypes suggesting more precise interaction of highly virulent strains of Hp in eliciting severe tissue damage. In conclusion, the study demonstrates close relationship between the plasma malondialdehyde and nitric oxide levels, gastric histopathology and genotypes of H. pylori.


Asunto(s)
Enfermedades Gastrointestinales/sangre , Enfermedades Gastrointestinales/microbiología , Infecciones por Helicobacter/sangre , Helicobacter pylori/genética , Helicobacter pylori/patogenicidad , Malondialdehído/sangre , Óxido Nítrico/sangre , Adulto , Femenino , Gastritis/sangre , Gastritis/microbiología , Gastritis/patología , Gastritis Atrófica/sangre , Gastritis Atrófica/microbiología , Gastritis Atrófica/patología , Enfermedades Gastrointestinales/patología , Genotipo , Infecciones por Helicobacter/genética , Infecciones por Helicobacter/patología , Helicobacter pylori/aislamiento & purificación , Humanos , Intestinos/microbiología , Intestinos/patología , Masculino , Metaplasia/sangre , Metaplasia/microbiología , Metaplasia/patología , Persona de Mediana Edad , Neoplasias Gástricas/sangre , Neoplasias Gástricas/microbiología , Neoplasias Gástricas/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA